# Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

> **NCT06475352** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 400 (estimated)

## Conditions studied

- Digestive Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** CAPOX regimen

## Key facts

- **NCT ID:** NCT06475352
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-04
- **Final completion:** 2030-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475352, "Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06475352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*